TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05417698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Only (Ex only)
Description: Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Mediterranean Diet (Ex + MedDiet)
Description: Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
Study: NCT05557721

Intervention type: PROCEDURE
Intervention: Topical lidocaine
Description: Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.

Intervention type: PROCEDURE
Intervention: MP-TLT
Description: Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning.
Study: NCT06218511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide-based hepatocellular carcinoma vaccine IMA970A
Description: IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
Study: NCT05144789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS-DMPFC
Description: Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC or DMPFC
Description: The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study: NCT06219213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate serum
Description: Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate serum
Description: Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate serum
Description: Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream A
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream B
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glyceryl Eicosapentaenoate Cream C
Description: Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
Study: NCT05995782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB418
Description: Oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB418
Description: Oral dose
Study: NCT06218511

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide (Adjuvant)
Description: Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
Study: NCT06095206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci094
Description: On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
Study: NCT06122935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Xi New Nomogram Software 2.0
Description: Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aurora Xi Currently Approved Software 1.3
Description: Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
Study: NCT05896306

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05705401

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Adjuvant Breast Radiation
Description: adjuvant breast radiotherapy per the current standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Description: participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
Study: NCT06185985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 (200mg to 600mg once daily)
Study: NCT05112315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predigraft
Description: The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
Study: NCT05763251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapy duration
Description: the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
Study: NCT05718804

Intervention type: OTHER
Intervention: Whether renal injury occurred and differences in intestinal flora
Description: Whether renal injury occurred and differences in intestinal flora

Intervention type: OTHER
Intervention: Whether renal injury occurred and differences in intestinal flora
Description: Whether renal injury occurred and differences in intestinal flora
Study: NCT05228860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vida Sana (a Group Lifestyle Intervention)
Description: Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental Healthy Food Deliveries
Description: Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental Healthy Food Deliveries
Description: Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)
Study: NCT05893121

Intervention type: OTHER
Intervention: Cardiac coherence session
Description: A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.

Intervention type: OTHER
Intervention: Information note about MRI
Description: explanatory note about MRI examination

Intervention type: OTHER
Intervention: Information note about MRI
Description: explanatory note about MRI examination
Study: NCT06533280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Study: NCT04589611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amobarbital/Gel-One (one dose)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amobarbital/Gel-One (one dose)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (single dose)
Description: One dose of placebo during the initial surgical intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amobarbital/Gel-One (two doses)
Description: One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (two doses)
Description: One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Study: NCT06533280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Study: NCT05739123

Intervention type: DRUG
Intervention: Relugolix-Containing Product
Description: Any relugolix-containing therapy
Study: NCT05964257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Study: NCT04844866

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MB-CART2019.1
Description: MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Study: NCT04378907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
Study: NCT04844866

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: MB-CART2019.1
Description: MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-GemOx or BR plus polatuzumab vedotin
Description: Immunochemotherapy will be administered as per arm description.
Study: NCT05398120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Group
Description: Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
Study: NCT04378907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Lab Session, 30 watts
Description: During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
Study: NCT04899427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
Study: NCT05754996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifuroxazide
Description: Nifuroxazide dosing : 200 mg capsule four times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
Study: NCT06533280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A, C and D: VH3739937 500 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: VH3739937 100 mg
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A and C: Placebo
Description: Oral administration of Placebo in moderate fat/moderate calorie conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A and C: Placebo
Description: Oral administration of Placebo in moderate fat/moderate calorie conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment A
Description: VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment B
Description: VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment C
Description: VH3739937, 500 mg single tablet administered under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment D
Description: VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Treatment E
Description: VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D: Probe cocktail
Description: Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
Study: NCT04886596

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV_1 dose group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV_annual group.
Study: NCT05453682

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypo-IMRT
Description: Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
Study: NCT05499481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.
Study: NCT05976854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal education
Description: The standard prenatal education is based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.

Intervention type: OTHER
Group type: OTHER
Intervention: Prenatal education
Description: The standard prenatal education is based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.